Strong investor demand drives heavy oversubscription in Sudeep Pharma’s ₹895 crore IPO

Investors reviewing Sudeep Pharma’s public issue noted significant demand across categories, with overall subscription reaching 93.71 times by the close. The issue included a ₹95 crore fresh component and an ₹800 crore offer for sale, priced at ₹563–593 per share and finalised at the upper end of the band. Market participants highlighted the QIB segment’s 213.08 times subscription as a key indicator of institutional confidence, supported by the company’s position in high entry barrier excipients and speciality nutrition ingredients.